ArticleScientific reports2026
Assessing willingness to pay for HLA-B*58:01 genetic testing before allopurinol initiation and its potential impact on future health policy, Thailand.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assessed patients with gout regarding their willingness to pay (WTP) for Human Leukocyte Antigen type-B* 58:01 (HLA-B*58:01) genetic testing before starting allopurinol and identified factors influencing WTP, including the cost of alternative urate-lowering therapy (ULT). A cross-sectional study was conducted using a validated, open-ended questionnaire. Participants over 20 years old were recruited from Naresuan University Hospital and three affiliated sub-district health-promoting hospitals. The majority were male, with a mean age of 64.52 ± 12.82 years. Most participants (86.00%) expressed WTP for the genetic testing, with high cost (62.86%) and insufficient income (25.71%) being the main reasons for un-WTP. Most could afford a median of THB 500 (USD 14.37). WTP for febuxostat, sulfinpyrazone, and benzbromarone was 68.00%, 67.60%, and 71.60%, respectively. Participants were willing to pay a median of THB 1000 (USD 28.74) for febuxostat or sulfinpyrazone, and THB 285 (USD 8.19) for benzbromarone. Multiple logistic regression showed that patient's income and health insurance type particularly non-Civil Servant Medical Benefit Scheme coverage were significantly associated with WTP for the genetic testing. Overall, most participants were willing to pay THB 500 (USD 14.36) for the genetic testing. The study provides insights for policymakers in pricing the genetic testing and ULT coverage in Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.